Seferović, PM;
Polovina, M;
Bauersachs, J;
Arad, M;
Gal, TB;
Lund, LH;
Felix, SB;
Arbustini, E;
Caforio, ALP;
Farmakis, D;
et al.
Seferović, PM; Polovina, M; Bauersachs, J; Arad, M; Gal, TB; Lund, LH; Felix, SB; Arbustini, E; Caforio, ALP; Farmakis, D; Filippatos, GS; Gialafos, E; Kanjuh, V; Krljanac, G; Limongelli, G; Linhart, A; Lyon, AR; Maksimović, R; Miličić, D; Milinković, I; Noutsias, M; Oto, A; Oto, Ö; Pavlović, SU; Piepoli, MF; Ristić, AD; Rosano, GMC; Seggewiss, H; Ašanin, M; Seferović, JP; Ruschitzka, F; Čelutkiene, J; Jaarsma, T; Mueller, C; Moura, B; Hill, L; Volterrani, M; Lopatin, Y; Metra, M; Backs, J; Mullens, W; Chioncel, O; de Boer, RA; Anker, S; Rapezzi, C; Coats, AJS; Tschöpe, C
(2019)
Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology.
Eur J Heart Fail, 21 (5).
pp. 553-576.
ISSN 1879-0844
https://doi.org/10.1002/ejhf.1461
SGUL Authors: Rosano, Giuseppe Massimo Claudio
![]() |
Microsoft Word (.docx)
Accepted Version
Available under License ["licenses_description_publisher" not defined]. Download (524kB) |
Abstract
Cardiomyopathies are a heterogeneous group of heart muscle diseases and an important cause of heart failure (HF). Current knowledge on incidence, pathophysiology and natural history of HF in cardiomyopathies is limited, and distinct features of their therapeutic responses have not been systematically addressed. Therefore, this position paper focuses on epidemiology, pathophysiology, natural history and latest developments in treatment of HF in patients with dilated (DCM), hypertrophic (HCM) and restrictive (RCM) cardiomyopathies. In DCM, HF with reduced ejection fraction (HFrEF) has high incidence and prevalence and represents the most frequent cause of death, despite improvements in treatment. In addition, advanced HF in DCM is one of the leading indications for heart transplantation. In HCM, HF with preserved ejection (HFpEF) affects most patients with obstructive, and ∼10% of patients with non-obstructive HCM. A timely treatment is important, since development of advanced HF, although rare in HCM, portends a poor prognosis. In RCM, HFpEF is common, while HFrEF occurs later and more frequently in amyloidosis or iron overload/haemochromatosis. Irrespective of RCM aetiology, HF is a harbinger of a poor outcome. Recent advances in our understanding of the mechanisms underlying the development of HF in cardiomyopathies have significant implications for therapeutic decision-making. In addition, new aetiology-specific treatment options (e.g. enzyme replacement therapy, transthyretin stabilizers, immunoadsorption, immunotherapy, etc.) have shown a potential to improve outcomes. Still, causative therapies of many cardiomyopathies are lacking, highlighting the need for the development of effective strategies to prevent and treat HF in cardiomyopathies.
Item Type: | Article | ||||||||
---|---|---|---|---|---|---|---|---|---|
Additional Information: | This is the peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited. | ||||||||
Keywords: | Dilated cardiomyopathy, Epidemiology, Heart failure, Hypertrophic cardiomyopathy, Management, Natural history, Pathophysiology, Peripartum cardiomyopathy, Restrictive cardiomyopathy, Cardiomyopathies, Cardiomyopathy, Dilated, Cardiomyopathy, Hypertrophic, Cardiomyopathy, Restrictive, Disease Management, Disease Progression, Female, Heart Failure, Heart Transplantation, Humans, Male, Pregnancy, Pregnancy Complications, Cardiovascular, Puerperal Disorders, Stroke Volume, Humans, Pregnancy Complications, Cardiovascular, Puerperal Disorders, Cardiomyopathy, Dilated, Cardiomyopathies, Cardiomyopathy, Hypertrophic, Cardiomyopathy, Restrictive, Disease Progression, Stroke Volume, Heart Transplantation, Pregnancy, Disease Management, Female, Male, Heart Failure, Heart failure, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, Restrictive cardiomyopathy, Peripartum cardiomyopathy, Epidemiology, Natural history, Pathophysiology, Management, Cardiovascular System & Hematology, 1102 Cardiorespiratory Medicine and Haematology | ||||||||
SGUL Research Institute / Research Centre: | Academic Structure > Molecular and Clinical Sciences Research Institute (MCS) | ||||||||
Journal or Publication Title: | Eur J Heart Fail | ||||||||
ISSN: | 1879-0844 | ||||||||
Language: | eng | ||||||||
Dates: |
|
||||||||
Publisher License: | Publisher's own licence | ||||||||
PubMed ID: | 30989768 | ||||||||
Web of Science ID: | WOS:000471307000006 | ||||||||
Go to PubMed abstract | |||||||||
URI: | https://openaccess.sgul.ac.uk/id/eprint/113837 | ||||||||
Publisher's version: | https://doi.org/10.1002/ejhf.1461 |
Statistics
Actions (login required)
![]() |
Edit Item |